Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2106 in Healthy Subjects
NCT05948059Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2023
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR-2106 in kidney transplantation (2 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Incidence and severity of adverse events at 6 months. Started Jul 2023; status: completed.
02
Drugs
SHR-2106
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT05948059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05948059.